How Much Does Jatenzo Cost in Oklahoma in 2026?

Oklahoma Retail Pricing for Jatenzo in 2026

The average cash-pay price for Jatenzo at Oklahoma retail pharmacies sits at approximately $900 per month in 2026, matching the Tolmar manufacturer list price. This figure applies across most chain and independent pharmacies statewide, with minimal variation between Oklahoma City, Tulsa, and smaller markets.

Jatenzo (oral testosterone undecanoate) received FDA approval in March 2019 as the first oral testosterone replacement therapy for adult men with hypogonadism caused by specific medical conditions. The key trial by Swerdloff et al. (2020) demonstrated that 87% of men receiving oral testosterone undecanoate achieved average serum testosterone concentrations within the normal range (300 to 1 to 100 ng/dL) by day 90. That efficacy finding supports the clinical rationale behind its pricing, but $900 monthly remains a real barrier for Oklahoma patients without prescription drug coverage.

Pricing also depends on the prescribed dose. Jatenzo capsules come in 158 mg and 198 mg strengths, with the starting dose typically set at 237 mg twice daily. Dose adjustments based on serum testosterone levels may push the monthly capsule count up or down, and some pharmacies price by capsule count rather than a flat monthly fee. Men on higher doses (up to 396 mg twice daily) may see slightly elevated costs at certain pharmacies.

Insurance Coverage in Oklahoma

Commercial insurance plans in Oklahoma vary widely in their formulary decisions regarding Jatenzo. Some Blue Cross Blue Shield of Oklahoma and UnitedHealthcare plans include Jatenzo on specialty tiers with prior authorization requirements, while others exclude it entirely in favor of injectable testosterone cypionate or topical gels.

Prior authorization criteria typically require documented serum testosterone below 300 ng/dL on two morning samples, a confirmed etiology of hypogonadism (not age-related decline alone per many plan definitions), and failure or intolerance of at least one first-line therapy such as injectable testosterone. The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with "unequivocally low serum testosterone concentrations" along with consistent signs and symptoms, and most Oklahoma insurers align their PA criteria with this guideline framework.

Copay amounts for Oklahoma patients with approved commercial coverage typically range from $50 to $150 per month on specialty tiers. Patients denied coverage should request a formal denial letter and work with their prescribing clinician on a peer-to-peer appeal, as overturn rates for testosterone therapy appeals have improved in recent years when clinical documentation is thorough.

Oklahoma Medicaid and Jatenzo

Oklahoma Medicaid does not cover Jatenzo. The state's preferred drug list for testosterone replacement includes injectable testosterone cypionate and select topical formulations, which cost a fraction of Jatenzo's retail price. This exclusion applies to both SoonerCare (Oklahoma's Medicaid program) fee-for-service and managed care enrollees.

Men enrolled in Oklahoma Medicaid who need testosterone replacement will typically receive injectable testosterone cypionate, which carries an average monthly cost to the state of $30 to $80 depending on dose and pharmacy. The FDA label for Jatenzo notes a specific cardiovascular monitoring requirement (blood pressure increases were observed in clinical trials), and state Medicaid pharmacy committees have cited both cost and this monitoring burden as factors in non-coverage decisions.

There is no current exception pathway for Jatenzo through Oklahoma Medicaid, even for patients who cannot tolerate injections or topicals. Patients in this situation may explore compounded oral testosterone undecanoate through 503A pharmacies (discussed below) or apply for the Tolmar manufacturer savings program independently, though savings cards cannot be applied to Medicaid prescriptions per federal anti-kickback rules.

Compounded Oral Testosterone Undecanoate in Oklahoma

Compounded oral testosterone undecanoate is available through licensed 503A compounding pharmacies in Oklahoma. These pharmacies operate under state Board of Pharmacy oversight and federal Section 503A of the Food, Drug, and Cosmetic Act, which permits patient-specific compounding with a valid prescription.

The cost picture changes dramatically with compounding. Some Oklahoma 503A pharmacies offer compounded oral testosterone undecanoate for significantly less than Jatenzo's $900 monthly retail price. Pricing depends on the compounding pharmacy, capsule strength, and quantity dispensed, but monthly costs at licensed compounders in the Oklahoma City and Tulsa metro areas have been reported in the $100 to $300 range.

A few critical distinctions separate compounded oral testosterone undecanoate from brand-name Jatenzo. Jatenzo uses a proprietary self-emulsifying drug delivery system (SEDDS) formulation that was specifically designed to improve oral bioavailability and received FDA approval based on the Swerdloff et al. pharmacokinetic data showing consistent absorption with food. Compounded versions may not replicate this exact formulation technology, which can result in different absorption profiles and less predictable serum testosterone levels.

The legality question is straightforward. Compounded oral testosterone undecanoate is legal in Oklahoma when dispensed by a licensed 503A pharmacy pursuant to a valid patient-specific prescription from a licensed prescriber. Oklahoma does not impose additional state-level restrictions on testosterone undecanoate compounding beyond standard Board of Pharmacy compounding regulations. Patients should verify that their chosen pharmacy holds a current Oklahoma Board of Pharmacy compounding license and follows USP 795 and USP 800 standards.

How the Tolmar Savings Card Works in Oklahoma

Tolmar Pharmaceuticals, the manufacturer of Jatenzo, offers a savings card program that can reduce monthly out-of-pocket costs for eligible commercially insured patients. The program is available to Oklahoma residents who meet the eligibility criteria.

Eligible patients are those with commercial prescription drug insurance. The savings card typically reduces copays to as low as $0 to $75 per month, depending on the specific terms of the current program cycle. Maximum annual benefit caps apply (often $7,200 to $9,600 per year). Patients must re-enroll annually, and Tolmar reserves the right to modify or discontinue the program.

Patients who are uninsured may also qualify for a separate Tolmar patient assistance program, though income verification and documentation requirements apply. Oklahoma patients should contact Tolmar directly or visit the Jatenzo website for current program terms, as benefit amounts and eligibility criteria change periodically.

Important exclusions apply. The savings card cannot be used by patients enrolled in Medicare, Medicaid, TRICARE, or any other federal or state government-funded healthcare program. This restriction exists because of federal regulations prohibiting manufacturer copay assistance for government-insured prescriptions. Oklahoma veterans receiving care through the VA system are similarly excluded from the savings card but should check the VA formulary, as the VA maintains its own drug pricing agreements.

Telehealth Access to Jatenzo in Oklahoma

Oklahoma permits telehealth prescribing of Jatenzo. This is significant for men in rural parts of the state where endocrinologists and urologists are scarce. A 2023 analysis in the Journal of the Endocrine Society noted that approximately 40% of Oklahoma counties lack a practicing endocrinologist, making telehealth an important access channel for hormone therapy.

Oklahoma's telehealth regulations allow prescribers to initiate testosterone therapy via audio-video consultation, provided they establish an appropriate clinician-patient relationship and order the required baseline labs (total testosterone, free testosterone, CBC, lipid panel, PSA for men over 40). Follow-up monitoring visits, including blood pressure checks required by the Jatenzo FDA label, can be conducted via telehealth as well, though periodic in-person blood pressure measurement is clinically advisable given the cardiovascular monitoring requirements noted in the prescribing information.

The Swerdloff et al. trial data showed mean systolic blood pressure increases of 3 to 5 mmHg in the oral testosterone undecanoate group compared to baseline [1]. Oklahoma clinicians prescribing via telehealth should establish a blood pressure monitoring protocol, whether through in-office visits, home blood pressure cuffs with validated readings, or pharmacy-based monitoring.

Comparing Jatenzo to Other TRT Options in Oklahoma

For Oklahoma men weighing Jatenzo against other testosterone replacement options, cost is often the deciding factor. Here is how the main options compare on a monthly basis at Oklahoma retail pharmacies.

Injectable testosterone cypionate (200 mg/mL, typical dose 100 to 200 mg every 1 to 2 weeks) runs $30 to $80 per month at most Oklahoma pharmacies. It requires intramuscular or subcutaneous injection and carries peak-and-trough fluctuations in serum levels. Topical testosterone gel (AndroGel 1.62%, Testim) costs $200 to $500 per month cash-pay, with the risk of transference to household contacts. Testosterone patches (Androderm) fall in the $300 to $600 monthly range with skin irritation as a common complaint. Jatenzo at $900 per month is the most expensive branded option but offers the convenience of twice-daily oral dosing without injection or transference risk.

A 2020 pharmacokinetic study within the Swerdloff et al. dataset confirmed that Jatenzo's oral SEDDS formulation achieved mean steady-state testosterone concentrations of 489 ng/dL (Cavg) with significantly less variability than older oral testosterone preparations. The clinical advantage of stable oral delivery is real, but whether it justifies the $820 monthly premium over injectable testosterone cypionate depends on the individual patient's needle aversion, lifestyle, and insurance situation.

For men whose primary concern is needle avoidance and who lack insurance coverage for Jatenzo, compounded oral testosterone undecanoate from a licensed Oklahoma 503A pharmacy or nasal testosterone (Natesto, approximately $500 to $700 per month) represent intermediate-cost alternatives worth discussing with a prescribing clinician.

Strategies to Reduce Jatenzo Costs in Oklahoma

Oklahoma patients have several concrete options to lower their monthly Jatenzo expense. Start by checking eligibility for the Tolmar savings card if commercially insured. Contact your insurance plan's pharmacy benefit manager to request a formulary exception or tier reduction, providing clinical documentation of injectable intolerance or contraindication.

Compare prices across Oklahoma pharmacies using GoodRx, RxSaver, or similar discount aggregators. Prices can vary by $50 to $100 between pharmacies in the same metro area. Independent pharmacies sometimes offer better cash-pay pricing than national chains for brand-name specialty drugs.

If brand Jatenzo remains unaffordable, discuss compounded oral testosterone undecanoate with your prescriber. Request a referral to a PCAB-accredited or state-licensed 503A compounding pharmacy in Oklahoma that has experience formulating testosterone undecanoate capsules. Monitor serum testosterone levels more frequently (every 4 to 6 weeks initially) when switching to a compounded product to confirm adequate absorption and dose appropriateness.

Patients should also ask about 90-day supply pricing, which sometimes offers a per-capsule discount compared to 30-day fills. Mail-order specialty pharmacies affiliated with Oklahoma-based health systems occasionally negotiate better pricing on branded specialty drugs than retail walk-in pharmacies.

The Oklahoma Insurance Department can assist patients who believe their insurer has improperly denied Jatenzo coverage. Filing a formal external review request is free and results in an independent medical review of the denial, which overturns the insurer's decision in a meaningful percentage of hormone therapy cases when clinical documentation supports medical necessity.